Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with

Read the full 235 word article

User Sign In